emetine | 7005-82-5

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吐根碱生物碱
• 英文名称: emetine
• 英文别名: Emetin；TCMDC-125849；Isoemetine, tetradehydro-；2-[(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-1-yl)methyl]-3-ethyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-benzo[a]quinolizine
• CAS: 7005-82-5
• 化学式: C₂₉H₄₀N₂O₄
• 分子量: 480.648
• InChiKey: AUVVAXYIELKVAI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  35
• 可旋转键数：
  7
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.59
• 拓扑面积：
  52.2
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• [EN] EMETINE DERIVATIVES, PRODRUGS CONTAINING SAME, AND METHODS OF TREATING CONDITIONS USING SAME<br/>[FR] DÉRIVÉS D'ÉMÉTINE, PRODROGUES CONTENANT CES DÉRIVÉS ET PROCÉDÉS DE TRAITEMENT DE TROUBLES AU MOYEN DE CES PRODROGUES
  申请人：UNIV HOWARD

  公开号：WO2012162175A1

  公开（公告）日：2012-11-29

  Compounds are provided herein which are emetine derivatives that can be used as prodrugs which selectively undergo activation to release emetine in specific cellular conditions. In one aspect, a blocking group is incorporated onto the emetine molecule by the derivization of the N2'-position with moieties that can be selectively removed by hydrolysis in the cancer/tumor microenvironment. Such compounds are less cytotoxic than emetine and are substantially inactive in non-cancerous cells. In one aspect, the compounds described herein can be used for the treatment of metastatic and non-metastatic cancers, including, for example, breast cancer, prostate cancer, lung cancer, and leukemia.

  本文提供了一些化合物，它们是伊美啶衍生物，可以用作前药，在特定细胞条件下选择性地发生活化以释放伊美啶。在一个方面，通过将阻断基固定到伊美啶分子上，通过在癌症/肿瘤微环境中选择性水解的方式，可以将其衍生化到N2'-位置。这种化合物比伊美啶更少细胞毒性，并在非癌细胞中基本无活性。在一个方面，本文描述的化合物可用于治疗转移性和非转移性癌症，包括乳腺癌、前列腺癌、肺癌和白血病等。
• Methods for Sensitizing Cancer Cells to Inhibitors
  申请人：Sherman Michael

  公开号：US20090062222A1

  公开（公告）日：2009-03-05

  The present invention is based on the discovery that inactivation of the heat shock response in cancer cells significantly enhances their sensitivity to proteasome and Hsp90 inhibitors. The inventors have discovered novel compounds which exhibit low toxicity, inhibit the heat shock protein response and sensitize cancer cells to anti-cancer therapies. In general, the heat shock protein inhibitors of the present invention share a common structure, namely a 2H-benzo[a]quinolizine tricyclic ring. Also encompassed are methods for a high throughput screen to identify heat shock inhibitors that sensitize cancer cells to anti-cancer therapies.
• Emetine Derivatives, Prodrugs Containing Same, And Methods Of Treating Conditions Using Same
  申请人：Bakare Oladapo

  公开号：US20140148377A1

  公开（公告）日：2014-05-29

  Compounds are provided herein which are emetine derivatives that can be used as prodrugs which selectively undergo activation to release emetine in specific cellular conditions. In one aspect, a blocking group is incorporated onto the emetine molecule by the derivization of the N2′-position with moieties that can be selectively removed by hydrolysis in the cancer/tumor microenvironment. Such compounds are less cytotoxic than emetine and are substantially inactive in non-cancerous cells. In one aspect, the compounds described herein can be used for the treatment of metastatic and non-metastatic cancers, including, for example, breast cancer, prostate cancer, lung cancer, and leukemia.
• US9492560B2
  申请人：——

  公开号：US9492560B2

  公开（公告）日：2016-11-15
• [EN] METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2<br/>[FR] MÉTHODES ET COMPOSITIONS POUR LE TRAITEMENT DU SARS-COV 2
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2021225767A1

  公开（公告）日：2021-11-11

  Disclosed herein are methods that are useful for treating a subject who has a pathogenic infection, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); reducing the likelihood of the subject from being infected by a pathogen; and for reducing the transmission of a pathogen from a subject to others. The methods utilize a compound disclosed in Table 1 or Table 4 herein, optionally in combination with an additional agent such as an anti-infective agent.